JOINT MEETING

10TH BIC INTERNATIONAL CONFERENCE

CHAIRED BY:
P.M. MANNUCCI, Italy
F. PEYVANDI, Italy
N. CIAVARELLA, Italy
A.B. FEDERICI, Italy
S. LACROIX-DESCAZES, France
P.J. LENTING, France
D. LILLCRAP, Canada
J. VOORBERG, The Netherlands

GENOA ITALY 6-8 SEPTEMBER 2019

ORGANIZED BY

SISTEMA SOCIO SANITARIO
REGIONE LOMBARDIA

SCIENTIFIC COMMITTEE

CHAIRMED BY:
P.M. MANNUCCI, Italy
F. PEYVANDI, Italy
N. CIAVARELLA, Italy
A.B. FEDERICI, Italy
S. LACROIX-DESCAZES, France
P.J. LENTING, France
D. LILLCRAP, Canada
J. VOORBERG, The Netherlands

PROGRAMME
join the network

FOLLOW US ON FACEBOOK & TWITTER

BICinternationalconferencehemophilia

DOWNLOAD NOW THE SMC MEDIA EVENTS APP

BIC_hemophilia
The major innovations that were presented at the most recent events suggest that 2019 is a year of continuous development in treatment approaches and new drugs. Data from basic science research and clinical trials are outlining new scenarios, not only in gene therapy but also in the progress of replacement and non-replacement therapies with new drugs appearing in the market.

This joint meeting is meant to take the best of BIC & INHIBITORS International Conferences and feature only the most novel advances of basic science and clinical research in hemophilia, rare inherited coagulation disorders, von Willebrand factor and von Willebrand disease, gene therapy, the thrombotic microangiopathies (TTP, HUS and aHUS) and, of course, factor VIII inhibitors.

The most distinguished experts in the field will present their very latest data and offer their wisdom and insight into the current science developments, during a 3-day programme. We wish to welcome clinical and basic science researchers to the Joint 10th BIC & 3rd Inhibitors in Hemophilia International Conference and look forward to interacting with them throughout the whole 3-day period.

**The Scientific Committee**
P.M. Mannucci, F. Peyvandi
N. Ciavarella, A.B. Federici, S. Lacroix-Desmazes,
P. Lenting, D. Lillicrap, J. Voorberg
Replacement therapies in hemophilia A and B - Efficacy of extended half-life products
Chairs: David Lillicrap (Canada), Pier Mannuccio Mannucci (Italy)

08:30
Real life data: real benefits. What have we achieved?
Pratima Chowdari (UK)

09:00
How to optimize the use of extended half-life products (PK analysis)
Alfonso Iorio (Canada)

Safety of replacement therapies (standard and novel) (Part I)
Chairs: Nicola Ciavarella (Italy), Maria Elisa Mancuso (Italy)

09:30
Which bleeding phenotype can we expect in severe hemophilia A previously untreated patients treated with non replacement therapies?
Karin Fijn van Draat (The Netherlands)

10:00
How safety of novel anti-hemophilic drugs should be approached. Known and unknown adverse effects
Flora Peyvandi (Italy)

10:30
Are Fc - factor VIII (FVIII) products less immunogenic? New clinical data?
Christoph Königs (Germany)

11:00
Break

Safety of replacement therapies (standard and novel) (Part II)
Chairs: Giovanni Di Minno (Italy), Mauro Biffoni (Italy)

11:30
Long-term side-effects of pegylated products: facts or fancies?
Silvio Garattini (Italy)

12:00
European pharmacovigilance of new products (with special emphasis on pegylated products)
Anneliese Hilger (EMA, Germany)

12:30
Immunogenicity of subcutaneous and intravenous drugs
David Lillicrap (Canada)

13:00
Lunch Satellite Symposium:
Evolution by design: advancing the standard of care in hemophilia A
Sponsored by Bayer
(not accredited for CME)
Chair: Erik Berntorp (Sweden)

How evolution leads to revolution in hemophilia care
Erik Berntorp (Sweden)

Advances driven by evolution: investigating the role of factor VIII (FVIII) in coagulation and beyond
Hermann Eichler (Germany)

Advances driven by design: using real-life practice to guide clinical studies (results from PROTECT VIII)
Elena Santagostino (Italy)

Q&A

Satellite Symposium:
ADAMTS13 and von Willebrand factor (VWF): progressing patient care through protein innovation
Sponsored by Takeda
(not accredited for CME)
Chair: Flora Peyvandi (Italy)

Welcome and introduction
Flora Peyvandi (Italy)
The ADAMTS13-von Willebrand factor (VWF) interaction: clinical implications & applications
Peter Lenting (France)

Congenital thrombotic thrombocytopenic purpura (cTTP) as a chronic disease: what is the long-term view to achieve more optimal outcomes?
Paul Coppo (France)

The role of von Willebrand factor (VWF) in individualized care for patients with von Willebrand disease (VWD)
Andreas Tiede (Germany)

Panel discussion
Facilitated by Flora Peyvandi (Italy)

Meeting summary and close
Flora Peyvandi (Italy)

15:00 Satellite Lecture:
Von Willebrand factor (VWF) and factor VIII (FVIII): an unending love affair
Sponsored by Kedrion (not accredited for CME)
Chair: Prasad Mathew (USA)

Setting the stage
Prasad Mathew (USA)

Clinical implications of this love story for patients with hemophilia A
Maria Elisa Mancuso (Italy)

Q&A

15:30 Break

16:00 Keynote Lecture “Choice of assays for novel anti-hemophilic therapies”
Armando Tripodi (Italy)
Chair: Wolfgang Schramm (Germany)

The role of von Willebrand factor (VWF) in factor VIII (FVIII) immunogenicity
Chairs: Giancarlo Castaman (Italy), Augusto B. Federici (Italy)

Factor VIII (FVIII) peptide presentation to the immune system; modulation by von Willebrand factor (VWF)
Jan Voorberg (The Netherlands)

High von Willebrand factor (VWF) affinity factor VIII (FVIII) and immunogenicity
Peter Lenting (France)

16:30

17:00

17:30 Walking Poster Session
See ePoster programme for details
Non-replacement therapies in the hemophilias: update
Chairs: Peter Lenting (France), Jan Voorberg (The Netherlands)

09:00
Fitusiran
Steven Pipe (USA)

09:30
APC serpin
James Huntington (UK)

10:00
Anti-TFPI
Alan Mast (USA)

10:30
Thrombotic microangiopathy associated with emicizumab: views from an insider
Paul Coppo (France)

11:00
Break

Novel drugs
Chair: Paul Coppo (France)

11:30
Caplacizumab: results of phase II/phase III studies
Marie A. Scully (UK)

12:00
Satellite Lecture: Treatment of bleeding episodes in the era of non-factor replacement therapies
Sponsored by Novo Nordisk
(not accredited for CME)
Chair: Pratima Chowdary (UK)
Welcome & introduction
Pratima Chowdary (UK)

Concomitant use of rFVIIa and emicizumab in congenital haemophilia A with inhibitors: safety data from the HAVEN clinical programme
Stephanie Seremetis (USA)

Subcutaneous prophylaxis with concizumab in patients with haemophilia A and haemophilia A/B with inhibitors: Phase 2 trial results
Giancarlo Castaman (Italy)

Q&A

Satellite Lecture: From trials to clinical practice: emergent treatments to overcome challenges in people with haemophilia A
Sponsored by Roche
(not accredited for CME)
Chair: Flora Peyvandi (Italy)
Speaker: Amy Shapiro (USA)

Lunch Satellite Symposium: Can we improve inhibitor management in patients with haemophilia A? Clinical approaches to inhibitor prevention and elimination
Sponsored by Octapharma
(not accredited for CME)
Chair: Jan Astermark (Sweden)

The challenge of inhibitors in haemophilia A - Introduction
Jan Astermark (Sweden)

Immune tolerance induction in haemophilia A - challenges, experience and future approaches
Carmen Escuriola (Germany)

ITI in the context of new therapies for haemophilia A: the Atlanta and MOTIVATE studies
Robert Sidonio (USA)

Final results from the NuProtect study of Nuwiq® in previously untreated patients
Ri Liesner (UK)

Q&A
**Gene Therapy**

**Chairs:** Steven Pipe (USA), Amy Shapiro (USA)

14:00

Phagocytosis-shielded lentiviral vectors for hemophilia gene therapy
Alessio Cantore (Italy)

16:00

Liver toxicity in gene therapy
Edward Tuddenham (UK)

14:30

Oral Communications - Hemophilia

Targeting of hepatocyte subpopulation contributing to liver post-natal growth is crucial for maintenance of transgene expression in liver-directed gene therapy
Michela Milani (Italy)

Transplantation of fetal liver cells into newborn hemophilic mice for the treatment of hemophilia A without inhibitors formation
Simone Merlin (Italy)

B-AMAZE, a Phase 1/2 trial of a novel investigational adeno associated virus (AAV) gene therapy (FLT180a) in subjects with severe or moderately severe hemophilia B (HB)
Pratima Chowdary (UK)

Developing a novel coagulation factor VIII with reduced immunogenicity by a direct deimmunization approach
Karina Winterling (Germany)

Recombinant, patient-derived FVIII-neutralising antibodies: a platform for research, product testing, and ex vivo modelling of haemophilia A
Carmen Coxon (UK)

Towards the transplacental delivery of maternal FVIII to FVIII-deficient progeny for induction of active immune tolerance to therapeutic FVIII
Angelina Mimoun (France)

15:00

Break

Immunotolerance induction in hemophilia (Part I)

**Chairs:** Maria Elisa Mancuso (Italy), Kathleen Pratt (USA)

16:30

How to maintain tolerance in hemophilia A
Sébastien Lacroix-Desmazes (France)

17:00

How to induce Treg responses in experimental hemophilia A
Naro Biswas (USA)

Is it important to induce immune tolerance in the era of non-replacement therapies?
Elena Santagostino (Italy)

17:30

Specific Treg therapy for hemophilia inhibitors: CARs versus BARs?
David Scott (USA)

18:00

Walking Poster Session
See ePoster programme for details

18:30
Von Willebrand factor (VWF) and ADAMTS13 in hemostasis and thrombosis (Part I)

Chairs: Ilaria Mancini (Italy), Karen Vanhoorelbeke (Belgium)

09:00
Von Willebrand factor (VWF) self-association role in hemostasis and thrombosis
José López (USA)

09:30
Interactions of von Willebrand factor (VWF)/ADAMTS13
Jim Crawley (UK)

10:00
Modulation of ADAMTS13 conformation (open/close) in thrombotic thrombocytopenic purpura (TTP)
Karen Vanhoorelbeke (Belgium)

10:30
Impact of cohort studies on therapeutic approaches for von Willebrand disease (VWD)
Jeroen Eikenboom (The Netherlands)

11:00
Break

Von Willebrand factor (VWF) and ADAMTS13 in hemostasis and thrombosis (Part II)

Chairs: Ilaria Mancini (Italy), Karen Vanhoorelbeke (Belgium)

11:30
Update on 3WINTERS
Augusto B. Federici (Italy)

12:00
Acquired von Willebrand disease (VWD)
Giancarlo Castaman (Italy)

12:30
Role of von Willebrand factor (VWF) in the vessel wall: interplay with vascular smooth muscle cells
Cécile Denis (France)

13:00
Lunch

Oral Communications - Von Willebrand factor (VWF) and ADAMTS 13

09:00
Von Willebrand factor (VWF) production and secretion, and endothelial cell characteristics in healthy ECFCs; Generating a valid ex vivo model for von Willebrand disease (VWD)
Suzan De Boer (The Netherlands)

Inhibition of ADAMTS13 prevents the loss of high molecular weight von Willebrand factor (VWF) multimers in an in vitro left ventricular assist device
Shannen Deconinck (Belgium)

Conformation of ADAMTS13 in the French cohort of child-onset thrombotic thrombocytopenic purpura
Bérangère Joly (France)

Patient anti-ADAMTS13 autoantibodies induce an open ADAMTS13 conformation in immune mediated thrombotic thrombocytopenic purpura
Elien Roose (France)

Tilting the balance: A trade-off between thrombotic thrombocytopenic purpura (TTP) patients autoantibody binding and proteolytic activity of ADAMTS13 variants
Nuno Alexandre Gomes Graça (The Netherlands)

In-depth epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura patients using a large library of ADAMTS13 fragments
Kadri Kangro (Belgium)
Other clinical challenges of hemophilia

**Chairs:** Massimo Morfini (Italy), Elena Santagostino (Italy)

- **15:00** Thrombosis in hemophilia: results from EUHASS registry, including thrombotic microangiopathies
  Michael Makris (UK)

- **15:30** Ageing with hemophilia
  Pier Mannuccio Mannucci (Italy)

- **16:00** Eradication of HCV in Europe
  Massimo Colombo (Italy)

- **16:30** Break

Immunotolerance induction in hemophilia (Part II)

**Chairs:** Sébastien Lacroix-Desmazes (France), Carmen Escuriola (Germany)

- **17:00** Gene-therapy-mediated tolerance induction
  Valder R. Arruda (USA)

- **17:30** A working group on new concepts for ITI
  Kathleen Pratt (USA)

- **18:00** End of the Conference
Friday, 6TH SEPTEMBER

17:30  rFVIIIFc for first-time immune tolerance induction (ITI) therapy: interim results from the global, prospective verITI-8 study
L. Malec (USA)

17:40  Brazilian registry of persons with hemophilia A receiving emicizumab (emicizumab cases, EMCase Project)
R. Camelo (Brazil)

17:50  Nature of FVIII-containing immune complexes and induction of immune tolerance in patients with hemophilia A
M. Bou Jadeh (France)

18:00  Performance of a clinical risk prediction model for inhibitor formation in severe hemophilia A
S. Hassan (The Netherlands)

18:10  Real-World efficacy and safety data of patients with hemophilia and inhibitors treated with aPCC: “FEIBA global outcome Study (FEIBA-GO)”, results from >12 months follow-up
V. Cano (Switzerland)

18:20  The timing of initial exposures to FVIII treatment in nonsevere hemophilia A
A. Abdi (The Netherlands)

Saturday, 7TH SEPTEMBER

18:30  In-depth epitope mapping of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura patients using a large library of ADAMTS13 fragments
K. Kangro (Belgium)

18:40  APAC, a dual AntiPlatelet and AntiCoagulant, towards a local vascular targeting antithrombotic
R. Lassila (Finland)

18:50  Investigation of the ADAMTS13 c.3178C>T mutation in hereditary and acquired thrombotic thrombocytopenic purpura
G. Sinkovits (Hungary)

19:00  Rare bleeding disorders in the pediatric population of Northern Greece: a 10-year single center experience
A. Adramerina (Greece)

19:10  Successful treatment and durable remission of refractory thrombotic thrombocytopenic purpura (TTP) with belimumab
R. Woods (USA)
Friday, 6TH SEPTEMBER

17:30 Immune tolerance induction rescue (ITI-R) with human-cl rhFVIII in hemophilia A patients and high-titre inhibitors
S. Pasca (Italy)

17:40 Usefulness of global haemostasis assays in hemophilia A patients with discrepant bleeding phenotype
M. Milos (Croatia)

17:50 Visual inspection of the aPTT reaction curve as a reliable screening tool for detecting the presence of FVIII and FIX inhibitors
J. Pavic (Bosnia and Herzegovina)

18:00 Comparison of the effect of cationic and anionic polyamidoamine dendrimers on components of coagulation system
L. Mukhametova (Russia)

18:10 Prospective study of the immunological response to factor VIII in severe hemophilia A patients during immune tolerance induction treatment
S. Rossini (Italy)

18:20 Accurate factor VIII concentrate dosing by ideal body weight in overweight and obese hemophilia A patients
T. Goedhart (The Netherlands)

Saturday, 7TH SEPTEMBER

18:30 The presence of anti-ADAMTS13 autoantibodies in immune-mediated thrombotic thrombocytopenic purpura patients does not hamper correct determination of ADAMTS13 antigen levels
C. Dekimpe (Belgium)

18:40 Single-sample detection of anti-ADAMTS13 autoantibodies using fiber-optic surface plasmon resonance technology
C. Dekimpe (Belgium)

18:50 BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease
F. Atiq (The Netherlands)

19:00 Analytical performance validation of a new screening assay for the deficiency of ADAMTS-13 activity
N. Binder (Austria)

19:10 Feasibility of a new fully automated ADAMTS-13 activity assay
N. Binder (Austria)
Baseline patient characteristics in ReITIrade - a prospective study of rescue ITI with recombinant factor VIII Fc (rFVIII Fc) in patients who have failed previous ITI attempts
C. Königs (Germany)

Transplantation of fetal liver cells into newborn hemophilic mice for the treatment of hemophilia A without inhibitors formation
S. Merlin (Italy)

LIFE-ACTIVE: observational study evaluating the physical activity in a subset of damocog alfa pegol treated hemophilia A patients who are enrolled in the HEM-POWR study
E. Musi (Switzerland)

Observational immune tolerance induction study (ObsITI): Immune tolerance induction with a single factor VIII/von Willebrand factor concentrate for treatment of hemophilia A patients with inhibitors
C. Escuriola (Germany)

MOTIVATE: MOdern Treatment of Inhibitor-positiVe pATIEnts with hemophilia A - An international observational study
C. Escuriola (Germany)

Structural Evidence of an Anti-Factor C1 Domain Antibody Bound to B Domain-Deleted factor VIII
P.C. Spiegel (USA)

Type 1 VWD caused by a novel dominant p.Thr274Pro mutation localized in VWF propeptide
L. Baronciani (Italy)

Evaluation of the von Willebrand factor (VWF) inhibitor in a large cohort of European and Iranian patients previously diagnosed with type 3 von Willebrand disease (VWD) enrolled into the 3WINTER-IPS Project
L. Baronciani (Italy)

Current view on the safety of PEGylated biologics in hemophilia treatment
A. Baumann (Germany)

The presence of inhibitors against von Willebrand factor and factor VIII in the same patient: a case report
D. Coen Herak (Croatia)

Evaluation of platelet-dependent VWF activity on a heterogeneous group of von Willebrand disease patients using four different methods: two VWF:GPIbM and two VWF:RCo assays
P. Colpani (Italy)
Management of acquired hemophilia A: a case series  
S. Varvello (Italy)

17:40 Immune tolerance induction with Nuwiq® (Simoctocog Alfa) in nine patients with severe hemophilia A and inhibitors to FVIII  
R. Liesner (UK)

17:50 Final results from the NuProtect study of Nuwiq® (simoctocog alfa) treatment in previously untreated patients with severe hemophilia A  
R. Liesner (UK)

18:00 Combination of emicizumab with simoctocog alfa for prophylaxis in previously untreated/minimally treated hemophilia A patients, and for managing inhibitor patients  
R. Sidonio (USA)

18:10 Population pharmacokinetic model for recombinant factor VIII Fc fusion protein (rFVIIIFc) validated and optimized for use in children  
L. Bukkems (The Netherlands)

18:20 The combination of plasma-derived FVIII/VWF with emicizumab has non-additive effects on thrombin generation assay independently of the presence of inhibitors in hemophilia A plasma  
A. Pérez (Spain)

18:30 Prognostic value of polymorphisms of the CYP2C19 gene in the development of stent thrombosis  
A. Zhunuspekova (Croatia)

18:40 Six years of experience with plasma fractionation industries at a private super speciality hospital in south India: renaissance in usage of excess plasma in blood banks  
B.B. Poluru Mranikrinda (India)

18:50 Evaluation of the chromogenic assay “Biophen factor IX” on Sysmex CS-2400 analyzer  
C. Novembrino (Italy)

19:00 Testing clot growth and thrombin wave patterns in hemophilia patients  
C. Kluft (The Netherlands)

19:10 Overview of efficacy and safety of a plasma-derived human von Willebrand factor concentrate for perioperative management and delivery in patients with hereditary VWF deficiency, unresponsive to dDAVP  
F. Bridey (France)
Friday, 6th September

17:30 Recombinant, patient-derived FVIII-neutralising antibodies: a platform for research, product testing, and ex vivo modelling of hemophilia A  
C. Coxon (UK)

17:40 Use of chromogenic factor VIII activity determination in hemophilia A plasma of patients under emicizumab treatment  
N. Binder (Austria)

17:50 Performance evaluation of a new fully automated thrombin generation instrument for the measurement of TGA in hemophilia samples  
N. Binder (Austria)

18:00 ADAMTS13 Inhibitor assessment with the hemosil Acustar ADAMTS13 activity assay  
C. Valsecchi (Italy)

Saturday, 7th September

18:30 Thrombin and plasmin generation in patients with plasminogen or plasminogen activator inhibitor type 1 deficiency  
J. Saes (The Netherlands)

18:40 Quantification of VWF propeptide release before and after desmopressin in von Willebrand disease and hemophilia A  
L. Bukkems (The Netherlands)

18:50 In vitro and in vivo modulation of von Willebrand factor gene mutations with dominant-negative effect  
C. Casari (Italy)

19:00 Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura  
I. Mancini (Italy)

19:10 Non-specific non-antiphospholipid inhibitor in a 26-years-old woman: a case report with few answers and many questions  
N. Ciavarella (Italy)
THURSDAY 5TH SEPTEMBER

Welcome dinner
Inner city stories - A dinner in denim

We are pleased to invite you to the Welcome Dinner on Thursday, September 5th, in a superb medioeval historical location in the heart of Genova: the Museo Diocesano Cloister. An al-fresco soirée whose main theme is the art of textiles. The Welcome Dinner is a seated buffet meal, ongoing until 10:30 pm. Show up when you wish and taste our right-out-of-the-oven focaccia and the other delicacies that are prepared on the spot. During the dinner it will be also possible to visit the museum’s room dedicated to one peculiar type of textile that was created in Genoa: denim.

DRESS CODE: Denim

FRIDAY 6TH SEPTEMBER

Conference dinner
The Countryside - A Zero-KM dinner

On Friday, September 6th, we are hiking to all the way to the mountainside behind Genoa for a charming dinner with a country flavour, at Agriturismo E-Reixe (Farmhouse restaurant The Roots), located in the village of Sant’Olcese. An old-fashioned torpedo will take us up there, and you will get to taste the delicacies of Liguria, hand made (and home grown) in the Agriturismo.

DRESS CODE: Smart casual, flat shoes preferred

SATURDAY 7TH SEPTEMBER

Arrivederci dinner
Vitamin Sea

On Saturday, September 7th, we will say Arrivederci with a chic dinner on the seaside, in the village of Boccadasse, one of the most peculiar fishing villages of the Genoa Area. The restaurant boasts a set of spectacular glass windows facing right onto the sea, where we will taste a fish-based menu while listening to the waves crashing by.

DRESS CODE: Laid-back chic

Please reserve your dinners at the Registration Desk
V.R. ARRUDA (USA)
University of Pennsylvania - Perelman School of Medicine - The Children’s Hospital of Philadelphia, Philadelphia, USA

M. BIFFONI (ITALY)
National Institute of Health, Rome, Italy

N. BISWAS (USA)
Gene and Cell Therapy Group - Wells Center for Pediatric Research, Indianapolis, USA

A. CANTORE (ITALY)
Vita-Salute San Raffaele University, Milan, Italy

G. CASTAMAN (ITALY)
Center for Bleeding Disorders and Coagulation, Careggi University Hospital, Florence, Italy

P. CHOWDARY (UK)
KD Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust, London, UK

N. CIAVARELLA (ITALY)
Hemophilia and Thrombosis Center of the Bari University Hospital; Technical Panel on Thrombosis of the Apulia Region, Bari, Italy

M. COLOMBO (ITALY)
Humanitas Research Hospital, Milan, Italy

P. COPPO (FRANCE)
French reference Centre for Thrombotic Microangiopathies, Saint-Antoine Hospital, Paris, France

J. CRAWLEY (UK)
Centre for Haematology, Imperial College London, London, UK

C. DENIS (FRANCE)
Institut National de la Santé et de la Recherche Médicale (INSERM) U1176, Le Kremlin-Bicêtre, France

G. DI MINNO (ITALY)
Clinical and Experimental Medicine, University of Naples Federico II, Naples, Italy

J. EIKENBOOM (THE NETHERLANDS)
Leiden University Medical Center, Leiden, The Netherlands

C. ESCURIOLA (GERMANY)
Haemophilia Centre Rhein Main - (HZRM), Frankfurt, Germany

A.B. FEDERICI (ITALY)
University of Milan, Hospital L. Sacco, University ASST Fatebenefratelli-Sacco, Milan, Italy

K. FIJN VAN DRAAT (THE NETHERLANDS)
University of Amsterdam, Amsterdam, The Netherlands

S. GARATTINI (ITALY)
Institute “Mario Negri” - IRCCS, Milan, Italy

A. HILGER (GERMANY)
Federal Institute for Vaccines and Biomedicines, Langen, Germany

J. HUNTINGTON (UK)
University of Cambridge, Cambridge Institute for Medical Research, Cambridge, United Kingdom
A. Iorio (Canada)
McMaster University, Hamilton, Canada

C. Königs (Germany)
Klinische und molekulare Hämostaseologie, Klinik für Kinder- und Jugendmedizin, Universitätsklinikum Frankfurt, Frankfurt, Germany

S. Lacroix-Demaszes (France)
Institut National de la Santé et de la Recherche Médicale (INSERM), UMR 1138, Centre de Recherche des Cordeliers Paris, France

P.J. Lenting (France)
Inserm U770, Le Kremlin-Bicêtre, France

D. Lillicrap (Canada)
Richardson Laboratory, Queen’s University, Kingston, Canada

J.A. López (USA)
Bloodworks Northwest Research Institute, University of Washington, School of Medicine, Seattle, USA

M. Makris (UK)
University of Sheffield, Sheffield Haemophilia and Thrombosis Centre, Sheffield, UK

I. Mancini (Italy)
University of Milan and Luigi Villa Foundation, Milan, Italy

P.M. Mannucci (Italy)
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy

M.E. Mancuso (Italy)
Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy

A. Mast (USA)
Medical College of Wisconsin, Wauwatosa, USA

M. Morfini (Italy)
Associazione Italiana Centri Emofilia (AICE), Florence, Italy

F. Peyvandi (Italy)
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

S. Pipe (USA)
University of Michigan, Special Coagulation Laboratory, Michigan, USA

K. Pratt (USA)
Uniformed Services University of the Health Sciences, Maryland, USA

E. Santagostino (Italy)
President of Italian Association of Hemophilia Centres (AICE), Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

D. Scott (USA)
Uniformed Services University of Health Sciences, Bethesda, USA

W. Schramm (Germany)
Universität München - Rudolf Marx Stiftung, München, Germany

M. Scully (UK)
University College Hospital, London, UK

A. Shapiro (USA)
Indiana Hemophilia & Thrombosis Center, Indianapolis, USA

A. Tripodi (Italy)
Humanitas University, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Maggiore Hospital Foundation, Milan, Italy

E. Tuddenham (UK)
University College London, Royal Free Hospital Trust, London, UK

K. Vanhoorelbeke (Belgium)
Campus Kulak Kortrijk, KU Leuven Kortrijk, Belgium

J. Voorberg (The Netherlands)
Sanquin Research and University of Amsterdam, Amsterdam, The Netherlands
Conference Venue:
Palazzo Ducale
Piazza Giacomo Matteotti, 9 - Genoa (Preferred entrance: Piazza De Ferrari)

CME accreditation:
Italian Continuing Medical Education
The Conference has been accredited for Italian CME: event n. 266836 (20 credits). Professions involved: Physician (Allergology, Hematology, Genetics, Internal Medicine, Nephrology, Orthopedics, Transfusion Medicine, Clinical Pathology), Biologist (Biologist).

EACCME Accreditation
The Conference has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with 18 European CME credits (ECMEC®s). Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 CreditsTM. Information on the process to convert EACCME® credit to AMA credit can be found at www.ama-assn.org/education/earn-credit-participation-international-activities. Live educational activities, occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

EthicalMedTech Compliance
MedTech Europe Code of Ethical Business Practice: Compliant.
Reference number: EMT18465

Italian CME accreditation managed by:
EMS GROUP Euro Medical Service S.r.l.
Provider ECM ID 3765
Email: info@emsgroup.it - www.emsgroup.it

International Accreditation and EthicalMedTech Compliance managed by:
SMC Media srl
Via Giovenale, 7 - Milan - Italy
congress@smc-media.com - www.smc-media.com

On-site secretariat is open at:
Thursdays 5 Sept. 18:00-20:00  Fridays 6 Sept. 7:30-18:30  Saturdays 7 Sept. 8:30-19:00  Sundays 8 Sept. 8:30-18:00

⭐ Staff may be available beyond these hours and dates for urgent matters ⭐
10th BIC International Conference

JOINT MEETING

WITH THE CONTRIBUTION OF

MAJOR SPONSORS

BAYER

octapharma

Takeda

SPONSORS

BIOVITRx

CSL Behring

Grifols

Kedrion Biopharma

Novo Nordisk

Sanofi Genzyme

Sobi

ORGANIZING SECRETARIAT: SMC Media Srl
Phone: +39 02 8341 9430/1
Email: info@smc-media.com - congress@smc-media.com
Liberate Life builds on our dedication to opening up opportunities for people living with haemophilia by individualising treatment for increased protection. Liberate Life is about living life beyond haemophilia, and celebrating life without compromise.

At Sobi, we are transforming the lives of people affected by rare diseases. We have a wealth of experience in haemophilia and are dedicated to positive change and long-term commitment to transforming the lives of people affected by it.

liberatelif.eu